{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:42:45Z","timestamp":1780627365327,"version":"3.54.1"},"reference-count":97,"publisher":"Elsevier","isbn-type":[{"value":"9780323994347","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA046487"],"award-info":[{"award-number":["DA046487"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.pmbts.2022.06.017","type":"book-chapter","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T08:29:45Z","timestamp":1659688185000},"page":"153-176","source":"Crossref","is-referenced-by-count":20,"title":["Opioid signaling and design of analgesics"],"prefix":"10.1016","member":"78","reference":[{"issue":"5","key":"10.1016\/bs.pmbts.2022.06.017_bb0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40263-022-00914-4","article-title":"Central neuropathic pain syndromes: current and emerging pharmacological strategies","volume":"36","author":"Gurba","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0015","article-title":"Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study","volume":"354","author":"Arf\u00e8","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/bs.pmbts.2022.06.017_bb0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3164\/jcbn.10-79","article-title":"The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine","volume":"48","author":"Matsui","year":"2011","journal-title":"J Clin Biochem Nutr"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0025","first-page":"180","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective","author":"Bindu","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/bs.pmbts.2022.06.017_bb0030","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1097\/j.pain.0000000000000608","article-title":"Gabapentin loses efficacy over time after nerve injury in rats: role of glutamate transporter-1 in the locus coeruleus","volume":"157","author":"Kimura","year":"2016","journal-title":"Pain"},{"issue":"1","key":"10.1016\/bs.pmbts.2022.06.017_bb0035","first-page":"22","article-title":"SSRI antidepressant medications: adverse effects and tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"1","key":"10.1016\/bs.pmbts.2022.06.017_bb0040","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities HHS public access","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0045","article-title":"Strategies towards safer opioid analgesics\u2014a review of old and upcoming targets","author":"Varga","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/bs.pmbts.2022.06.017_bb0050","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tips.2016.01.001","article-title":"New technologies for elucidating opioid receptor function","volume":"37","author":"Bruchas","year":"2016","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2022.06.017_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41594-017-0011-7","article-title":"Structure and dynamics of GPCR signaling complexes","volume":"25","author":"Hilger","year":"2018","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"10.1016\/bs.pmbts.2022.06.017_bb0060","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2019.04.021","article-title":"Structural insights into the process of GPCR-G protein complex formation","volume":"177","author":"Liu","year":"2019","journal-title":"Cell"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-3233(07)74004-4","article-title":"Activation of G protein-coupled receptors","volume":"74","author":"Deupi","year":"2007","journal-title":"Adv Protein Chem"},{"issue":"6","key":"10.1016\/bs.pmbts.2022.06.017_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neuropharm.2018.11.010","article-title":"Arrestin recruitment and signaling by G protein-coupled receptor heteromers","volume":"152","author":"Mores","year":"2019","journal-title":"Neuropharmacology"},{"issue":"7366","key":"10.1016\/bs.pmbts.2022.06.017_bb0080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature10361","article-title":"Crystal structure of the \u03922Adrenergic receptor-Gs protein complex","volume":"477","author":"Rasmussen","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/bs.pmbts.2022.06.017_bb0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2017.07.002","article-title":"Identification of phosphorylation codes for arrestin recruitment by G protein-coupled receptors","volume":"170","author":"Zhou","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/bs.pmbts.2022.06.017_bb0090","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1124\/pr.111.004598","article-title":"Functional selectivity at the \u03bc-opioid receptor: implications for understanding opioid analgesia and tolerance","volume":"63","author":"Raehal","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0095","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.3390\/molecules25184257","article-title":"Biased opioid ligands","author":"Faouzi","year":"2020","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/bs.pmbts.2022.06.017_bb0100","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","article-title":"Mechanisms of signalling and biased agonism in G protein-coupled receptors","volume":"19","author":"Wootten","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"22","key":"10.1016\/bs.pmbts.2022.06.017_bb0105","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1021\/acs.jmedchem.0c00901","article-title":"Synthesis and pharmacology of a novel \u03bc-\u03b4opioid receptor heteromer-selective agonist based on the carfentanyl template","volume":"63","author":"Faouzi","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0110","article-title":"The life cycle of the Mu-opioid receptor","volume":"27","author":"Cuitavi","year":"2020","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2022.06.017_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased \u03bc-opioid receptors improve analgesia and diminish tolerance but Worsen opioid side effects","volume":"10","author":"Kliewer","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The G protein-biased \u03ba-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo","volume":"352","author":"White","year":"2015","journal-title":"J Pharmacol Exp Ther Am Soc"},{"issue":"13","key":"10.1016\/bs.pmbts.2022.06.017_bb0125","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/bph.15004","article-title":"Morphine-Induced respiratory depression is independent of \u03b2-arrestin2 signalling","volume":"177","author":"Kliewer","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"18","key":"10.1016\/bs.pmbts.2022.06.017_bb0130","doi-asserted-by":"crossref","first-page":"13873","DOI":"10.1021\/acs.jmedchem.1c01273","article-title":"A novel mitragynine analog with low-efficacy Mu opioid receptor agonism displays antinociception with attenuated adverse effects","volume":"64","author":"Chakraborty","year":"2021","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/bs.pmbts.2022.06.017_bb0135","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1046\/j.1360-0443.1999.9479612.x","article-title":"Mechanisms of fatal opioid overdose","volume":"94","author":"White","year":"1999","journal-title":"Addiction"},{"issue":"6813","key":"10.1016\/bs.pmbts.2022.06.017_bb0140","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/35047086","article-title":"\u03bc-Opioid receptor desensitization by \u03b2-arrestin-2 determines morphine tolerance but not dependence","volume":"408","author":"Bohn","year":"2000","journal-title":"Nature"},{"issue":"5449","key":"10.1016\/bs.pmbts.2022.06.017_bb0145","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking \u03b2-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science"},{"issue":"3","key":"10.1016\/bs.pmbts.2022.06.017_bb0150","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in \u03b2-arrestin 2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"625","key":"10.1016\/bs.pmbts.2022.06.017_bb0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci Signal"},{"issue":"4","key":"10.1016\/bs.pmbts.2022.06.017_bb0160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.tibs.2020.10.002","article-title":"The life cycle of the mu-opioid receptor","volume":"46","author":"Cuitavi","year":"2021","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0165","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.56519","article-title":"Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site","volume":"10","author":"Uprety","year":"2021","journal-title":"Elife"},{"issue":"1","key":"10.1016\/bs.pmbts.2022.06.017_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-23736-2","article-title":"Site selective C\u2013H functionalization of mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy","volume":"12","author":"Bhowmik","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0175","first-page":"410","article-title":"Intrinsic efficacy of opioid ligands and its importance for apparent bias, operational analysis, and therapeutic window","volume":"1","author":"Gillis","year":"2020","journal-title":"Mol Pharmacol Am Soc Pharmacol Exp Ther"},{"issue":"7619","key":"10.1016\/bs.pmbts.2022.06.017_bb0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0185","doi-asserted-by":"crossref","DOI":"10.1111\/bph.14805","article-title":"Functional characterization of a novel opioid, PZM21, and its influence on behavioural responses to morphine","author":"Kudla","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/bs.pmbts.2022.06.017_bb0190","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.bja.2020.06.057","article-title":"Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased Mu opioid receptor agonist PZM21 in non-human primates","volume":"125","author":"Ding","year":"2020","journal-title":"Br J Anaesth"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0195","series-title":"FDA approves new opioid for intravenous use in hospitals, other controlled clinical settings","author":"Office of the Commissioner","year":"2020"},{"issue":"3","key":"10.1016\/bs.pmbts.2022.06.017_bb0200","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G-protein-biased ligand at the \u03bc-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphines","volume":"344","author":"DeWire","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113986","article-title":"Synthesis, biological, and structural explorations of a series of \u03bc-opioid receptor (MOR) agonists with high G protein signaling bias","volume":"228","author":"Yang","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/bs.pmbts.2022.06.017_bb0210","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: an overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/bs.pmbts.2022.06.017_bb0215","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/syn.21914","article-title":"Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants","volume":"70","author":"Grinnell","year":"2016","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/bs.pmbts.2022.06.017_bb0220","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1124\/jpet.109.156711","article-title":"Nociceptin\/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin\/orphanin FQ\/\u03bc-opioid receptor agonists","volume":"331","author":"Khroyan","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/bs.pmbts.2022.06.017_bb0225","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","article-title":"Current knowledge of buprenorphine and its unique pharmacological profile","volume":"10","author":"Pergolizzi","year":"2010","journal-title":"Pain Pract"},{"issue":"suppl 1","key":"10.1016\/bs.pmbts.2022.06.017_bb0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1191\/0269216306pm1126oa","article-title":"Opioid-induced respiratory effects: new data on buprenorphine","volume":"20","author":"Dahan","year":"2006","journal-title":"Palliat Med"},{"issue":"09","key":"10.1016\/bs.pmbts.2022.06.017_bb0235","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1017\/S146114571400025X","article-title":"Rewarding or aversive effects of buprenorphine\/naloxone combination (suboxone) depend on conditioning trial duration","volume":"17","author":"Canestrelli","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/bs.pmbts.2022.06.017_bb0240","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/bs.pmbts.2022.06.017_bb0245","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1097\/CCM.0b013e318265680a","article-title":"Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice","volume":"40","author":"Alhaddad","year":"2012","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/bs.pmbts.2022.06.017_bb0250","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/ALN.0b013e318238fea0","article-title":"Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active","volume":"115","author":"Brown","year":"2011","journal-title":"Anesthesiology"},{"issue":"22","key":"10.1016\/bs.pmbts.2022.06.017_bb0255","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0024-3205(97)00160-4","article-title":"Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes","volume":"60","author":"Iribarne","year":"1997","journal-title":"Life Sci"},{"issue":"32","key":"10.1016\/bs.pmbts.2022.06.017_bb0260","doi-asserted-by":"crossref","first-page":"10331","DOI":"10.1523\/JNEUROSCI.23-32-10331.2003","article-title":"Buprenorphine-induced antinociception is mediated by Mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors","volume":"23","author":"Lutfy","year":"2003","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/bs.pmbts.2022.06.017_bb0265","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s10571-020-01034-7","article-title":"Kratom alkaloids, natural and semi-synthetic, show less physical dependence and ameliorate opioid withdrawal","volume":"41","author":"Wilson","year":"2021","journal-title":"Cell Mol Neurobiol"},{"issue":"18","key":"10.1016\/bs.pmbts.2022.06.017_bb0270","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1021\/acs.biochem.0c00629","article-title":"Natural products for the treatment of pain: chemistry and pharmacology of Salvinorin A, mitragynine, and collybolide","volume":"60","author":"Chakraborty","year":"2020","journal-title":"Biochemistry"},{"issue":"21","key":"10.1016\/bs.pmbts.2022.06.017_bb0275","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1021\/jacs.6b00360","article-title":"Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators","volume":"138","author":"Kruegel","year":"2016","journal-title":"J Am Chem Soc"},{"issue":"6","key":"10.1016\/bs.pmbts.2022.06.017_bb0280","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1021\/acscentsci.9b00141","article-title":"7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects","volume":"5","author":"Kruegel","year":"2019","journal-title":"ACS Cent Sci"},{"issue":"11","key":"10.1016\/bs.pmbts.2022.06.017_bb0285","article-title":"Evaluation of kratom opioid derivatives as potential treatment option for alcohol use disorder","volume":"12","author":"Gutridge","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/bs.pmbts.2022.06.017_bb0290","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/bph.14913","article-title":"G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder","volume":"177","author":"Gutridge","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"18","key":"10.1016\/bs.pmbts.2022.06.017_bb0295","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","article-title":"Mitragynine\/corynantheidine pseudoindoxyls as opioid analgesics with Mu agonism and delta antagonism, which do not recruit \u03b2-arrestin-2","volume":"59","author":"V\u00e1radi","year":"2016","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/bs.pmbts.2022.06.017_bb0300","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.biochem.0c00658","article-title":"Predicted mode of binding to and allosteric modulation of the \u03bc-opioid receptor by Kratom's alkaloids with reported antinociception in vivo","volume":"60","author":"Zhou","year":"2020","journal-title":"Biochemistry"},{"issue":"14","key":"10.1016\/bs.pmbts.2022.06.017_bb0305","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1021\/acschemneuro.1c00149","article-title":"Kratom alkaloids as probes for opioid receptor function: pharmacological characterization of minor indole and oxindole alkaloids from Kratom","volume":"12","author":"Chakraborty","year":"2021","journal-title":"ACS Chem Neurosci"},{"issue":"22","key":"10.1016\/bs.pmbts.2022.06.017_bb0310","doi-asserted-by":"crossref","first-page":"16553","DOI":"10.1021\/acs.jmedchem.1c01111","article-title":"Oxidative metabolism as a modulator of Kratom's biological actions","volume":"64","author":"Chakraborty","year":"2021","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/bs.pmbts.2022.06.017_bb0315","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41589-020-0535-8","article-title":"TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome","volume":"16","author":"Olsen","year":"2020","journal-title":"Nat Chem Biol"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0320","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1124\/jpet.120.000134","article-title":"Strategies for developing k opioid receptor agonists for the treatment of pain with fewer side effects","volume":"1","author":"Paton","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/bs.pmbts.2022.06.017_bb0325","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.neuron.2019.02.029","article-title":"Pain-induced negative affect is mediated via recruitment of the nucleus accumbens kappa opioid system","volume":"102","author":"Massaly","year":"2019","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/bs.pmbts.2022.06.017_bb0330","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.neuron.2011.06.011","article-title":"Selective P38\u03b1 MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction","volume":"71","author":"Bruchas","year":"2011","journal-title":"Neuron"},{"issue":"37","key":"10.1016\/bs.pmbts.2022.06.017_bb0335","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1523\/JNEUROSCI.2444-15.2015","article-title":"Kappa opioid receptor-induced aversion requires P38 MAPK activation in VTA dopamine neurons","volume":"35","author":"Ehrich","year":"2015","journal-title":"J Neurosci"},{"issue":"51","key":"10.1016\/bs.pmbts.2022.06.017_bb0340","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M113.504381","article-title":"Development of functionally selective, small molecule agonists at kappa opioid receptors","volume":"288","author":"Zhou","year":"2013","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/bs.pmbts.2022.06.017_bb0345","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00213-020-05519-7","article-title":"Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys","volume":"237","author":"Huskinson","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"456","key":"10.1016\/bs.pmbts.2022.06.017_bb0350","doi-asserted-by":"crossref","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","article-title":"Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria","volume":"9","author":"Brust","year":"2016","journal-title":"Sci Signal"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0355","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","article-title":"Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor","volume":"32","author":"Schattauer","year":"2017","journal-title":"Cell Signal"},{"issue":"5","key":"10.1016\/bs.pmbts.2022.06.017_bb0360","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","article-title":"Phosphoproteomic approach for agonist-specific signaling in mouse brains: MTOR pathway is involved in \u03ba opioid aversion","volume":"44","author":"Liu","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/bs.pmbts.2022.06.017_bb0365","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.118.255661","article-title":"Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the Mu opioid receptor-targeting agonist morphine","volume":"371","author":"Kaski","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/bs.pmbts.2022.06.017_bb0370","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/hepr.12830","article-title":"Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial","volume":"47","author":"Kumada","year":"2017","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/bs.pmbts.2022.06.017_bb0375","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000341268","article-title":"Efficacy and safety of a novel \u0138-agonist for managing intractable pruritus in dialysis patients","volume":"36","author":"Kumagai","year":"2012","journal-title":"Am J Nephrol"},{"issue":"7","key":"10.1016\/bs.pmbts.2022.06.017_bb0380","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1021\/acsmedchemlett.7b00224","article-title":"Seeking (and finding) biased ligands of the kappa opioid receptor","volume":"8","author":"Bohn","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0385","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/mol.113.089649","article-title":"Identification of novel functionally selective K-opioid receptor scaffolds S","volume":"85","author":"White","year":"2014","journal-title":"Mol Pharmacol"},{"issue":"32","key":"10.1016\/bs.pmbts.2022.06.017_bb0390","doi-asserted-by":"crossref","first-page":"27050","DOI":"10.1074\/jbc.C112.387332","article-title":"6\u2032-Guanidinonaltrindole (6\u2032-GNTI) is a G protein-biased \u03ba-opioid receptor agonist that inhibits arrestin recruitment","volume":"287","author":"Rives","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0395","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1126\/scisignal.aar4309","article-title":"G Protein signaling-biased agonism at the k-opioid receptor is maintained in striatal neurons","volume":"11","author":"Ho","year":"2018","journal-title":"Sci Signal"},{"issue":"11","key":"10.1016\/bs.pmbts.2022.06.017_bb0400","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/bph.13474","article-title":"The G-protein biased partial \u03ba opioid receptor agonist 6\u2032-GNTI blocks hippocampal paroxysmal discharges without inducing aversion","volume":"173","author":"Zangrandi","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/bs.pmbts.2022.06.017_bb0405","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0028-3908(91)90068-M","article-title":"The dopamine D2 agonists RU 24213 and RU 24926 are also KAPPA-opioid receptor antagonists","volume":"30","author":"Fortin","year":"1991","journal-title":"Neuropharmacology"},{"issue":"15","key":"10.1016\/bs.pmbts.2022.06.017_bb0410","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/bph.13854","article-title":"Selective \u03ba receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice","volume":"174","author":"Spetea","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0415","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1021\/acs.jmedchem.7b00981","article-title":"Highly potent and selective new diphenethylamines interacting with the \u03ba-opioid receptor: synthesis, pharmacology, and structure\u2212activity relationships","volume":"60","author":"Erli","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0420","article-title":"Structure-based evolution of G protein-biased \u03bc-opioid receptor agonists","author":"Wang","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2022.06.017_bb0425","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cell.2017.12.011","article-title":"Structure of the nanobody-stabilized active state of the kappa opioid receptor","volume":"172","author":"Che","year":"2018","journal-title":"Cell"},{"issue":"11","key":"10.1016\/bs.pmbts.2022.06.017_bb0430","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/acschemneuro.5b00153","article-title":"Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior","volume":"6","author":"V\u00e1radi","year":"2015","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"10.1016\/bs.pmbts.2022.06.017_bb0435","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1124\/mol.110.066613","article-title":"\u03bc-Opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization","volume":"78","author":"McPherson","year":"2010","journal-title":"Mol Pharmacol"},{"issue":"7","key":"10.1016\/bs.pmbts.2022.06.017_bb0440","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bph.12222","article-title":"Efficacy and ligand bias at the \u03bc-opioid receptor","volume":"169","author":"Kelly","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/bs.pmbts.2022.06.017_bb0445","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0450","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54208","article-title":"Agonist-selective recruitment of engineered protein probes and of GRK2 by opioid receptors in living cells","volume":"9","author":"Stoeber","year":"2020","journal-title":"Elife"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108161","article-title":"In vitro functional assays as a tool to study new synthetic opioids at the \u03bc-opioid receptor: potential pitfalls and progress","volume":"235","author":"Vandeputte","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"48","key":"10.1016\/bs.pmbts.2022.06.017_bb0460","doi-asserted-by":"crossref","first-page":"12672","DOI":"10.1523\/JNEUROSCI.4569-08.2008","article-title":"\u03b4-Opioid receptor expression in the ventral tegmental area protects against elevated alcohol consumption","volume":"28","author":"Margolis","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0465","first-page":"bph.15409","article-title":"TRV130 partial agonism and capacity to induce anti-nociceptive tolerance revealed through reducing available \u039c-opioid receptor number","author":"Singleton","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"405","key":"10.1016\/bs.pmbts.2022.06.017_bb0470","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aab4068","article-title":"Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors","volume":"8","author":"Masuho","year":"2015","journal-title":"Sci Signal"},{"issue":"4","key":"10.1016\/bs.pmbts.2022.06.017_bb0475","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/mol.120.119404","article-title":"Unique pharmacological properties of the kappa opioid receptor signaling through gaz as shown with bioluminescence resonance energy transfer","volume":"98","author":"Barnett","year":"2020","journal-title":"Mol Pharmacol"},{"issue":"18","key":"10.1016\/bs.pmbts.2022.06.017_bb0480","doi-asserted-by":"crossref","first-page":"9984","DOI":"10.1073\/pnas.180194597","article-title":"Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs","volume":"97","author":"Yang","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/bs.pmbts.2022.06.017_bb0485","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.neuropharm.2003.11.024","article-title":"Deletion of guanine nucleotide binding protein \u0391z subunit in mice induces a gene dose dependent tolerance to morphine","volume":"46","author":"Leck","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pmbts.2022.06.017_bb0490","article-title":"Structural insights into distinct signaling profiles of the \u039cOR activated by diverse agonists","author":"Qu","year":"2021","journal-title":"bioRxiv"}],"container-title":["Progress in Molecular Biology and Translational Science","G Protein-Coupled Receptors - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117322000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117322000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:03:37Z","timestamp":1762560217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117322000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780323994347"],"references-count":97,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2022.06.017","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}